Bone cancer pain is one of the hardest problems a veterinarian has to manage, and the options are limited. A drug being developed for exactly that job just got a clearer route to market.
On October 5, Endovia Health Sciences and Lupvindol BioSciences announced that the FDA’s Center for Veterinary Medicine determined their investigational oral solution, CannEpil, qualifies as a “minor use” under the agency’s Minor Use and Minor Species program. The dvm360 report on the decision explains that the ruling makes the CBD and THC product eligible to pursue conditional approval.
Conditional approval lets a company sell a drug while it gathers the remaining effectiveness data, as long as it meets safety and manufacturing standards and shows a reasonable expectation of working. It lasts one year and can be renewed up to four more times.
What this means for your dog
CannEpil is not approved and not available today, so this is not something you can ask your vet for right now. If your dog is living with cancer pain, the practical step is still a conversation about the tools that already exist, from NSAIDs to other pain-control options. The company is scheduled to meet with the FDA on November 19, and any launch would be years off at best.
It is also a reminder not to reach for human CBD or THC products at home. Giving a dog cannabis meant for people can cause real harm, and THC is toxic to dogs. Dosing and safety belong with a vet. New pain options are arriving steadily in the meantime: see what the new three-month arthritis injection means, and why Apoquel overdoses are rising.